Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Más filtros

Bases de datos
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
Clin Exp Dermatol ; 39(4): 488-91, 2014 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-24779791

RESUMEN

Fumaric acid esters (FAEs) are effective in patients with moderate to severe psoriasis. Recent studies also report the efficacy of one FAE component, dimethylfumarate, in relapsing forms of multiple sclerosis (MS). We describe the case of a patient with MS who developed severe plaque psoriasis during interferon-ß-1a treatment for MS. The psoriasis was unresponsive to usual topical treatments and phototherapy. The patient was started on FAE 720 mg daily, with complete remission of the psoriatic lesions and neurological stabilization at follow-up at 24 months. Our case suggests that FAEs could represent a therapeutic option for patients with MS who develop plaque psoriasis following exposure to immune-modulating agents.


Asunto(s)
Erupciones por Medicamentos/tratamiento farmacológico , Fumaratos/uso terapéutico , Esclerosis Múltiple Recurrente-Remitente/tratamiento farmacológico , Psoriasis/tratamiento farmacológico , Adyuvantes Inmunológicos/efectos adversos , Ésteres , Humanos , Inmunosupresores , Interferón beta-1a , Interferón beta/efectos adversos , Masculino , Persona de Mediana Edad , Psoriasis/inducido químicamente , Resultado del Tratamiento
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA